545 related articles for article (PubMed ID: 9848296)
1. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
[TBL] [Abstract][Full Text] [Related]
3. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
[TBL] [Abstract][Full Text] [Related]
4. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
5. Effects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment.
Biljan MM; Lapensée L; Mahutte NG; Bissonnette F; Hemmings R; Tan SL
Fertil Steril; 2000 Nov; 74(5):941-5. PubMed ID: 11056237
[TBL] [Abstract][Full Text] [Related]
6. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
[TBL] [Abstract][Full Text] [Related]
7. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression.
Branigan EF; Estes MA
Fertil Steril; 2000 Mar; 73(3):587-90. PubMed ID: 10689017
[TBL] [Abstract][Full Text] [Related]
8. Programmed oocyte retrieval: clinical and biological effects of oral contraceptives administered before in vitro fertilization.
Mashiach S; Dor J; Goldenberg M; Shalev J; Levran D; Rudak E; Nebel L; Goldman B; Blankstein J; Ben-Rafael Z
Gynecol Endocrinol; 1989 Jun; 3(2):107-15. PubMed ID: 2816477
[TBL] [Abstract][Full Text] [Related]
9. Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study.
Huirne JA; Hugues JN; Pirard C; Fischl F; Sage JC; Pouly JL; Obruca A; Braat DM; van Loenen AC; Lambalk CB
Hum Reprod; 2006 Jun; 21(6):1408-15. PubMed ID: 16537563
[TBL] [Abstract][Full Text] [Related]
10. The significance of delayed suppression using buserelin acetate and recombinant follicle-stimulating hormone in a long protocol in vitro fertilization program.
Ravhon A; Aurell R; Lawrie H; Margara R; Winston RM
Fertil Steril; 2000 Feb; 73(2):325-9. PubMed ID: 10685537
[TBL] [Abstract][Full Text] [Related]
11. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N; Bastide A
Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
Scott JA; Brenner PF; Kletzky OA; Mishell DR
Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin suppression with oral contraceptives before in vitro fertilization.
Gonen Y; Jacobson W; Casper RF
Fertil Steril; 1990 Feb; 53(2):282-7. PubMed ID: 2105244
[TBL] [Abstract][Full Text] [Related]
15. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
16. Ovarian function during low-dose oral contraceptive use.
Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
[TBL] [Abstract][Full Text] [Related]
17. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
Ren J; Sha A; Han D; Li P; Geng J; Ma C
Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
19. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Borm G; Mannaerts B
Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
[TBL] [Abstract][Full Text] [Related]
20. Short-term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation.
Lindheim SR; Barad DH; Witt B; Ditkoff E; Sauer MV
J Assist Reprod Genet; 1996 Oct; 13(9):745-7. PubMed ID: 8947826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
